Polyrizon announces pricing of $4.2 million initial public offering and listing on the nasdaq capital market under new ticker “plrz”

Raanana, israel, oct. 28, 2024 (globe newswire) -- polyrizon ltd. (the "company" or "plrz"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the pricing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. aggregate gross proceeds are expected to be $4.2 million, prior to deducting underwriting discounts and offering expenses.
PLRZ Ratings Summary
PLRZ Quant Ranking